December 2023
1. HARRINGTON PR, Cong J, Troy SB, Rawson JMO, et al
   Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
   MMWR Morb Mortal Wkly Rep. 2023;72:1365-1370.
   

   >> Share

   
   
2. SMITH DJ, Lambrou A, Patel P
   SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
   MMWR Morb Mortal Wkly Rep. 2023;72:1357-1364.
   

   >> Share

   
   December 2022
3. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
   Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022.
   MMWR Morb Mortal Wkly Rep. 2022;71:1531-1537.
   

   >> Share

   
   October 2022
4. SULLIVAN M, Perrine CG, Kelleher J, Kanwar O, et al
   Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-August 28, 2022.
   MMWR Morb Mortal Wkly Rep. 2022;71:1384-1385.
   

   >> Share

   
   
5. BOEHMER TK, Koumans EH, Skillen EL, Kappelman MD, et al
   Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 - United States, January-July 2022.
   MMWR Morb Mortal Wkly Rep. 2022;71:1359-1365.
   

   >> Share

   
   June 2022
6. MALDEN DE, Hong V, Lewin BJ, Ackerson BK, et al
   Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
   MMWR Morb Mortal Wkly Rep. 2022;71:830-833.
   

   >> Share

   
   
7. GOLD JAW, Kelleher J, Magid J, Jackson BR, et al
   Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022.
   MMWR Morb Mortal Wkly Rep. 2022;71:825-829.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share